Neuropace Inc
NASDAQ:NPCE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sonadezi Long Thanh Shareholding Co
VN:SZL
|
VN |
|
Mitsubishi Chemical Holdings Corp
TSE:4188
|
JP |
|
Vericel Corp
NASDAQ:VCEL
|
US |
Neuropace Inc
Total Current Liabilities
Neuropace Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Neuropace Inc
NASDAQ:NPCE
|
Total Current Liabilities
$17.8m
|
CAGR 3-Years
17%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Total Current Liabilities
$5.4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Total Current Liabilities
$1.8B
|
CAGR 3-Years
21%
|
CAGR 5-Years
15%
|
CAGR 10-Years
14%
|
|
|
Stryker Corp
NYSE:SYK
|
Total Current Liabilities
$7.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
9%
|
CAGR 10-Years
8%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Total Current Liabilities
$16.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Total Current Liabilities
$2B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
15%
|
|
Neuropace Inc
Glance View
NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. The company is headquartered in Mountain View, California. The company went IPO on 2021-04-22. The firm is focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company’s novel and differentiated RNS System is the brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. The Company’s RNS System is a platform that delivers care for patients suffering from drug-resistant epilepsy and offers a personalized solution and outcomes to the patients suffering from other brain disorders. RNS System is a device that records brain activity data and clinicians to monitor patients. RNS System monitors the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is engaged in treating other brain disorders including depression, impulse control disorders, memory disorders, and post-traumatic stress.
See Also
What is Neuropace Inc's Total Current Liabilities?
Total Current Liabilities
17.8m
USD
Based on the financial report for Dec 31, 2025, Neuropace Inc's Total Current Liabilities amounts to 17.8m USD.
What is Neuropace Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
13%
Over the last year, the Total Current Liabilities growth was 18%. The average annual Total Current Liabilities growth rates for Neuropace Inc have been 17% over the past three years , 13% over the past five years .
